Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBITDA (2022 - 2025)

Historic EBITDA for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$53.9 million.

  • Centessa Pharmaceuticals' EBITDA fell 2808.92% to -$53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.2 million, marking a year-over-year decrease of 5141.89%. This contributed to the annual value of -$233.0 million for FY2024, which is 5735.64% down from last year.
  • Per Centessa Pharmaceuticals' latest filing, its EBITDA stood at -$53.9 million for Q3 2025, which was down 2808.92% from -$50.8 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year EBITDA high stood at -$23.3 million for Q2 2023, and its period low was -$109.2 million during Q4 2024.
  • Moreover, its 4-year median value for EBITDA was -$43.8 million (2024), whereas its average is -$48.8 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' EBITDA soared by 6451.93% in 2023, and later tumbled by 20233.09% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' EBITDA stood at -$43.0 million in 2022, then grew by 15.94% to -$36.1 million in 2023, then crashed by 202.33% to -$109.2 million in 2024, then soared by 50.66% to -$53.9 million in 2025.
  • Its EBITDA was -$53.9 million in Q3 2025, compared to -$50.8 million in Q2 2025 and -$28.3 million in Q1 2025.